| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Net income | -3.5 | -8.2 |
| EPS (diluted, $ a share) | $-0.04 | $-0.13 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
10-Q filed with the SEC, NASDAQ: GALT. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Galectin Therapeutics Inc: key numbers
- Share price
- $3.02Close, Nov 16
- Market cap
- $305M
- Shares outstanding
- 100.88MLatest SEC cover page
- Sector
- Life Sciences
- Industry
- Pharmaceutical PreparationsSIC 2834
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Galectin Therapeutics Inc
All →Galectin Therapeutics Financial Results
Galectin Therapeutics reported financial results for the quarter ended September 30, 2026, and provided a business update on its Phase 3 clinical trial protocol for belapectin in MASH cirrhosis. The company reached alignment with the FDA on the Phase 3 trial design and presented positive new analyses from its NAVIGATE trial at the AASLD Annual Meeting.
- Term
- 3 months
“New analyses were presented at AASLD, marking the fourth consecutive major liver conference where Galectin data was included in an oral presentation. We were extremely pleased by the positive feedback received on the oral presentation as well as the two poster presentations and are excited that our data was included in the AASLD conference highlights and the portal hypertension debrief.”
Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics
“As previously disclosed, we submitted our registrational Phase 3 protocol to FDA in the third quarter after reaching alignment on primary elements of the planned Phase 3 trial design. Additional information is expected to be presented at the Annual Stockholders’ Meeting on December 3, 2026.”
Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics